Researchers at the Francis Crick Institute have mapped the potential outcomes of changes to the VHL tumor-suppressing gene, a crucial step in understanding genetic variations linked to cancer. The study identified harmful VHL variants that increase kidney cancer risk and highlighted the impact of the HIF gene on tumor growth. Belzutifan, a drug inhibiting HIF, could be effective for those with specific VHL mutations. The researchers developed a scoring system to predict cancer-causing variants and are expanding their work to other cancer risk genes. This research could lead to more precise diagnostics and personalized treatments for cancer patients.
Source link
Scientists map all the possible outcomes of changes to key tumor-suppressing gene
